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Review
Several factors cause heterogeneity of response to antiretroviral therapy. Genetic polymorphisms, particularly in metabolizing
enzyme, cytochrome P450 isoenzymes and transport proteins MDR, MRP and SLC, may cause pharmacokinetic variability in
some ARVs, leading to viral failure, drug toxicity and may explain the interpatient variability for drug absorption pathways.
Objectives
Characterize the genetic profile of HIV-infected patients in the
Portuguese Population, from Santa Maria Hospital, Lisbon,
Portugal.
Single-Nucleotide Polymorphism
A total of 15 SNP, with pharmacogenetics relevance, located at 9
different genes, were genotyped by Microarray analysis. The SNP
were selected based on their involvement in drug metabolism and
according to the collection provided by the TaqMan® Drug
Metabolism Genotyping Assays.
Experimental Methods
Results
All SNP were in Hardy-Weinberg equilibrium except for CAR
NR1I3 rs2307424 (p=0.048), CYP2A6 rs28399435 (p= 0.000) and
CYP3A5 rs776746 (p=<0.0001), table 1.
Genotype frequencies for the gene/SNP are not the same among
the groups Caucasian and African (p-value < .05). As an example
we show 2 SNPs with significance CAR NR1I3 rs2307424
(p=0.005), and CYP3A5 rs776746 (p=0), table 2.
The comparison of SNP frequencies by gender doesn't show
statistical significance,, except for CYP3A5 rs776746 (allele
frequencies p=0.049) ( genotype frequencies p=0.007), table 3.
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Statistic Analysis
SNP ID Gene Assay ID Alleles tested n Samples tested
rs7662029 UGT2B7 C__30720663_20 G/A 345
rs1045642 ABCB1 C___7586657_20 G/A 359
rs9282564 ABCB1 C___2614970_10 C/T 349
rs1128503 ABCB1 C___7586662_10 G/A 353
rs2032582 ABCB1 C_11711720D_40 C/T 354
C_11711720C_30 C/A 354
rs2125739 ABCC10 C__16173668_10 C/T 340
rs1751034 ABCC4 C___1901918_30 C/T 357
rs2274407 ABCC4 C__16181780_20 C/A 345
rs28399435 CYP2A6 C__30634234_10 C/T 348
rs8192726 CYP2A6 C__29560333_20 C/A 357
rs3745274 CYP2B6 C___7817765_60 G/T 356
rs28399499 CYP2B6 C__60732328_20 C/T 354
rs776746 CYP3A5 C__26201809_30 C/T 332
rs41303343 CYP3A5 C__32287188_10 A/DEL 348
rs2307424 NR1I3 C__25746794_20 G/A 349
rs4149056 SLCO1B1 C__30633906_10 C/T 345
Population Characteristics
Table:1 Genotype and allele frequencies of the analysed polymorphisms
Gene/SNP Genotype /Allelic Caucasian  (%) African (%) P-value
CAR NR1I3 CC 90 31.58 29 10.18 0.005*
rs2307424 CT 104 36.49 13 4.56
TT 45 15.79 4 1.4
C 284 49.82 71 12.46 0.002*
T 194 34.04 21 3.68
CYP3A5 AA 0 0 23 7.9 0 (a)*
rs776746 AG 41 14.09 16 5.5
GG 204 70.1 7 2.41
A 41 7.04 62 10.65 0*
G 449 77.15 30 5.15
Gene/SNP N  Genotype  n  Freq.(%)  95% CI  P-value
CAR NR1I3 348 CC 152 43.68 (38.4,49.1) 0.048*
rs2307424 CT 143 41.09 (35.9,46.5)
TT 53 15.23 (11.7,19.5)
C 447 64.22 (60.5,67.8)
T 249 35.78 (32.2,39.5)
CYP2A6 345 AA 41 11.88 (8.8,15.9) 0.000*
rs28399435 AG 30 8.70 (6.0,12.3)
GG 274 79.42 (74.7,83.5)
A 112 16.23 (13.6,19.2)
G 578 83.77 (80.8,86.4)
CYP3A5 354 AA 28 7.91 (5.4,11.4) <0.0001*
rs776746 AG 67 18.93 (15.1,23.5)
GG 259 73.16 (68.2,77.7)
A 123 17.37 (14.7,20.4)
G 585 82.63 (79.6,85.3)
Gene/SNP  Genotype/Alellic Male  (%) Female (%) P-value
CYP3A5 AA 10 3.08 14 4.31 0.007*
rs776746 AG 47 14.46 15 4.62
GG 168 51.69 71 21.85
A 67 43 0.049*
G 383 157
Is composed of 367 individuals infected with HIV-1 receiving ARV
therapy. In terms of gender, 253 are male and 114 are female. In
relation to the race are 275 Caucasian, 114 African and 38
unknown.
Table:2 Allele and genotype frequencies and percentage of SNPs of CAR NR1I3 and CYP3A5 Genes per race.
Table 3: Frequencies and percentage per gender for CYP3A5 rs776746.
With the profile obtained by genetic characterization, performed in this study, we can conclude that the gene CYP3A5 rs776746
evidenced more heterogeneity in the population, according to the literature.
CYP3A5*3 (rs776746) the most common non-functional allele of the gene. Seems to be an import contributor to individual and inter
rational variation in CYP3A5 mediated metabolism of drugs.
Our study revealed a significant frequency of risk alleles associated with drug efficacy, safety and recommend dosage, namely CYP2A6,
CAR N and CYP3A5 rs776746. And therefore could provide clinical useful information on ART in HIV Portuguese population.
